Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy

Acta Haematologica

Volumn 120, Issue 4, 2009, Pages 195-198

  Christoforidou, A ^a,c   Pantelidou, D ^a   Anastasiadis, A ^a   Goutzouvelidis, A ^a   Margaritis, D ^a   Kotsianidis, I ^a   Spanoudakis, E ^a   Kaloutsi, V ^b   Bourikas, G ^a   Tsatalas, C ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYUREA; RECOMBINANT ALPHA INTERFERON; SALICYLIC ACID;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHROMELALGIA; FEMALE; HEMATURIA; HUMAN; LUNG EDEMA; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; QUINAZOLINES; THROMBOCYTHEMIA, ESSENTIAL;

EID: 58149154237     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000189381     Document Type: Article

References (10)

1. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S: Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-232.
2. Campbell PJ, Green AR: Management of polycythemia vera and essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2005:201-208.
3. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, the European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators: Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.
4. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Mico C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T, for the GIMEMA CMD-Working Party: Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008;93:372-380.
5. Lengfelder E, Griesshammer M, Hehlmann R: Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996;22(suppl 1):135-142.
6. Petrides PE: Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost 2006;32:399-408.
7. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-1953.
8. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Gugliotta L, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T: A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007;21:277-280.
9. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NCP, Gilliland DG, Kantarjian H: International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-1503.
10. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.